NEMUS Bioscience Partners With Atheln to Accelerate Drug Development Pipelines
COSTA MESA, CA (Marketwired, October 5, 2015) – Nemus Bioscience, Inc. (OTCQB: NMUS) has announced that it has signed a contract with Atheln, Inc., a California-based consulting group comprised of seasoned professionals skilled across the spectrum of drug development and product strategy, from chemistry/formulation to pre-clinical studies through NDA filing. Atheln will be focused on the development of the cannabinoid prodrug NB1111.
Biotech start-ups often have to balance program development based on limited resources, so hiring an array of full-time development talent is not cost-effective in the long-term, especially when there are multiple specialized pipeline projects.
Brian Murphy, M.D., Nemus CEO and Chief Medical Officer
Atheln affords Nemus the opportunity to bring world-class, highly experienced, professionals with expertise in specific functions to work on Nemus projects when they are most needed.
“Atheln looks forward to working with the Nemus team as they move to the vanguard of cannabinoid drug development,” commented Monica Alfaro Welling, Co-founder of Atheln. “For Atheln, this is a great opportunity to provide our integrated consulting approach across global CMC, regulatory, preclinical, clinical and new product planning functions, to this exciting new area of therapeutic development utilizing cannabinoids,” said Adriana Manzi, PhD, Co-founder of Atheln.
Brian Murphy added, “Through our Atheln relationship, we also have the regulatory consulting services of Judy Gordon, DVM, one of the preeminent ophthalmology regulatory experts in the country. Dr. Gordon has helped guide numerous products through the FDA assessment and approval process. Atheln’s expertise in ophthalmic product development complements the medical and research insights of Dr. Robert Weinreb. As recently announced, Dr Weinreb, a leading glaucoma expert and noted ophthalmology researcher at UC San Diego joined the NEMUS Scientific Advisory Board and will chair the Ophthalmology Board. This team will be invaluable as we move our cannabinoid prodrug through the development process,” stated Dr. Murphy.
“The Company has provided guidance that we are advancing a formulation of NB1111 into testing with our R&D collaborator, the University of Mississippi, prior to IND enabling studies and are looking to that data to support once-daily dosing of the prodrug” according to Murphy.
NEMUS Bioscience and the University of Mississippi entered into a research and in-licensing collaboration agreement in 2014.
ABOUT NEMUS BIOSCIENCE, INC.
Statements in this document that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “goal,” “focus,” “aims,” “believes,” “can,” “challenge,” “predictable” “will,” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make.
For more information, visit www.nemusbioscience.com
FORWARD LOOKING STATEMENTS
Statements in this document that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “goal,” “focus,” “aims,” “believes,” “can,” “challenge,” “predictable” “will,” or the negative of these terms or other comparable terminology. We operate in a rapidly-changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make.
Contact:
Investor Relations
Mike Cole
Vice President – MZ North America
Main: 949-259-4988
Mobile: 949-444-1341
mike.cole@mzgroup.us
www.mzgroup.us
SOURCE: Nemus Bioscience
